Dataset from A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009652
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of
oral AP24534 in a defined schedule in patients with refractory or advanced chronic
myelogenous leukemia and other refractory hematologic malignancies.
创建时间：
2024-11-26
